IMPT-314 is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to target both CD19 and CD20, two antigens present on B-cell lymphoma.

B-cell lymphoma is a type of non-Hodgkin lymphoma that originates in the B-cells. It is the most common type of lymphoma, comprising approximately 85% of all lymphomas in the United States. While the first generation of CD19 CAR T cell therapies delivered a major advance in treatment for patients with B-cell lymphoma, there remains a need for therapies that deliver more complete and durable responses. More than 40% of patients treated with a CD19 CAR T-cell therapy are not disease-free after treatment and 50% of patients who do respond, progress or relapse within six months.

Phase 1-2. The Phase 1-2 trial is a multi-center, open-label clinical trial designed to evaluate the tolerability and clinical benefit of IMPT-314 in patients with relapsed/refractory aggressive B-cell lymphoma and determine a recommended Phase 2 dose. More information can be found on ClinicalTrials.gov.

Next Milestone

Initiation of a pivotal trial expected in 2025

Commercial Rights

ROR1 is a highly expressed cell surface antigen present on many aggressive solid tumors, including approximately 50% of patients with ovarian and endometrial cancers.

Ovarian cancer is one of the leading causes of cancer deaths among women. Endometrial cancer is the most prevalent gynecological cancer and the sixth most common malignancy worldwide.

Phase 1. The Phase 1 open-label, dose-escalation and expansion clinical trial is designed to evaluate the safety and antitumor activity of LYL119 in patients with ROR1+ tumors. The initial cancer types to be evaluated will include ovarian and endometrial cancers, with subsequent expansion into tumor types including NSCLC and TNBC.

Next Milestone

Initial clinical data expected in 2H 2025

Commercial Rights